Search results for "Antiplatelet therapy"

showing 10 items of 13 documents

Atherothrombosis and Thromboembolism: Position Paper from the Second Maastricht Consensus Conference on Thrombosis

2018

AbstractAtherothrombosis is a leading cause of cardiovascular mortality and long-term morbidity. Platelets and coagulation proteases, interacting with circulating cells and in different vascular beds, modify several complex pathologies including atherosclerosis. In the second Maastricht Consensus Conference on Thrombosis, this theme was addressed by diverse scientists from bench to bedside. All presentations were discussed with audience members and the results of these discussions were incorporated in the final document that presents a state-of-the-art reflection of expert opinions and consensus recommendations regarding the following five topics: 1. Risk factors, biomarkers and plaque inst…

0301 basic medicinemedicine.medical_specialtyanticoagulantsADJUST ANTIPLATELET THERAPYPERCUTANEOUS CORONARY INTERVENTION030204 cardiovascular system & hematologyarterial thrombosisArticleantiplatelet therapyACTIVATED PROTEIN-CRED-BLOOD-CELLS03 medical and health sciences0302 clinical medicineVITAMIN-K ANTAGONISTSInternal medicineatherothrombosisIschaemic strokeNONVALVULAR ATRIAL-FIBRILLATIONmedicinePlateletatrial fibrillationACUTE ISCHEMIC-STROKEcoagulationATOMIC-FORCE MICROSCOPYCardiovascular mortalityischaemic strokeAtomic force microscopybusiness.industryConsensus conferenceHematologymedicine.diseaseThrombosis030104 developmental biologymyocardial infarctionCoagulationplateletsDIRECT ORAL ANTICOAGULANTSCardiologyPosition paperSYMPTOMATIC VENOUS THROMBOEMBOLISMatherosclerosisbusiness
researchProduct

A new approach to ticagrelor-based de-escalation of antiplatelet therapy after acute coronary syndrome. A rationale for a randomized, double-blind, p…

2021

The risk of ischemic events gradually decreases after acute coronary syndrome (ACS), reaching a stable level after 1 month, while the risk of bleeding remains steady during the whole period of dual antiplatelet treatment (DAPT). Several de-escalation strategies of antiplatelet treatment aiming to enhance safety of DAPT without depriving it of its efficacy have been evaluated so far. We hypothesized that reduction of the ticagrelor maintenance dose 1 month after ACS and its continuation until 12 months after ACS may improve adherence to antiplatelet treatment due to better tolerability compared with the standard dose of ticagrelor. Moreover, improved safety of treatment and preserved anti-is…

Acute coronary syndromemedicine.medical_specialtyELECTRA-SIRIO 2TicagrelorClinical CardiologyPlaceboantiplatelet therapylaw.inventionacute coronary syndrometicagrelorClinical studyPercutaneous Coronary InterventionRandomized controlled triallawInternal medicinemedicineHumansAcute Coronary SyndromeAspirinbusiness.industryMaintenance doseGeneral Medicinemedicine.diseasede-escalationTolerabilityELECTRA-SIRIO 2 ; acute coronary syndrome ; antiplatelet therapy ; de-escalation ; ticagrelorCardiologyCardiology and Cardiovascular MedicinebusinessTicagrelorDe-escalationPlatelet Aggregation Inhibitorsmedicine.drug
researchProduct

Impact of dual antiplatelet therapy with proton pump inhibitors on the outcome of patients with acute coronary syndrome undergoing drug-eluting stent…

2012

This study aimed to assess if proton pump inhibitors (PPIs) may reduce the effectiveness of clopidogrel, than H2 antagonist (anti-H2) in order to determine rehospitalization for acute coronary syndrome (re-ACS), target vessel revascularization (TVR) and cardiac death. This case-control study included 176 patients with ACS undergoing angioplasty (PCI) with drug-eluting stent implantation. The population was divided into two groups: PPI group (n=121) consisting of patients receiving at discharge dual antiplatelet therapy (DAT) plus PPI and anti-H2 group (n=55), consisting of patients receiving at discharge DAT + H2 receptor antagonist (H2RA). In a followup of 36 months the prevalence of ACS e…

Acute coronary syndromemedicine.medical_specialtyeducation.field_of_studyArticle Subjectbusiness.industrymedicine.medical_treatmentPopulationmedicine.diseaseClopidogrelEsomeprazoleSurgeryantiplatelet therapy PPIs clopidogrel anti-H2 ACS PCIDrug-eluting stentInternal medicineAngioplastyConventional PCImedicineCardiologyClinical StudyeducationbusinessOmeprazolemedicine.drug
researchProduct

Picotamide, a combined inhibitor of thromboxane A2 synthase and receptor, reduces 2-year mortality in diabetics with peripheral arterial disease: the…

2004

Aims Patients with diabetes are at excessive risk of mortality and cardiovascular morbidity. Previous studies suggest that aspirin may be less effective in diabetic patients. In this multi-centre, randomized, double blind trial picotamide, a dual inhibitor of thromboxane A2 synthase and receptor, was compared with aspirin for the prevention of mortality and major cardiovascular events in diabetics with peripheral arterial disease (PAD). Methods and results A total of 1209 adults aged 40–75 years with type 2 diabetes and PAD were randomized to receive picotamide (600 mg bid) or aspirin (320 mg od) for 24 months. The cumulative incidence of the 2 years overall mortality was significantly lowe…

AdultMalemedicine.medical_specialtyPhthalic AcidsType 2 diabetesDiabeteGastroenterologyThromboxane A2Double-Blind MethodRisk FactorsInternal medicineDiabetes mellitusPeripheral arterial diseasemedicineRisk of mortalityHumansPicotamideCumulative incidenceGeneral NursingAgedPeripheral Vascular DiseasesAspirinAspirinbiologybusiness.industryAntiplatelet therapyantiplatelet therapy; aspirin; diabetes; peripheral arterial disease; picotamide; thromboxane synthase inhibitorsMiddle Agedmedicine.diseaseSurvival AnalysisSurgeryThromboxane synthase inhibitors Indexed keywordsRelative riskbiology.proteinFemaleThromboxane-A synthasePicotamideCardiology and Cardiovascular MedicinebusinessDiabetic AngiopathiesPlatelet Aggregation InhibitorsFollow-Up Studiesmedicine.drugEuropean Heart Journal
researchProduct

Diabetic foot ulcers: Retrospective comparative analysis from Sicily between two eras

2021

Aim The aim of this study was to analyze changes in the incidence, management and mortality of DFU in Sicilian Type 2 diabetic patients hospitalized between two eras, i.e. 2008–2013 and 2014–2019. Methods We compared the two eras, era1: 2008–13, era2: 2014–19. In era 1, n = 149, and in era 2, n = 181 patients were retrospectively enrolled. Results In the population hospitalized for DFU in 2008–2013, 59.1% of males and 40.9% of females died, whilst in 2014–2019 65.9% of males and 34.1% of females died. Moderate chronic kidney disease (CKD) was significantly higher in patients that had died than in ones that were alive (33% vs. 43%, p < 0.001), just as CKD was severe (14.5% vs. 4%, p <…

MaleComorbidityAntiplatelet TherapyBiochemistrySettore MED/13 - EndocrinologiaEndocrinologyMedical ConditionsOral DiseasesRetrospective StudieChronic Kidney DiseaseMedicine and Health SciencesSurgical AmputationInsulinSicilyUlcersAged 80 and overMultidisciplinaryPharmaceuticsIncidenceQRMiddle AgedDiabetic FootType 2 DiabetesHospitalizationNephrologyMedicineFemaleHumanResearch ArticleEndocrine DisordersScienceOral MedicineSurgical and Invasive Medical ProceduresSigns and SymptomsLife ExpectancyDrug TherapyDiabetes MellitusRenal DiseasesHumansMortalityRenal Insufficiency ChronicAgedRetrospective StudiesDiabetic EndocrinologyBiology and Life SciencesHormonesDiabetes Mellitus Type 2Metabolic DisordersClinical MedicinePLoS ONE
researchProduct

Impact of periodontal treatment on the RANKL/OPG ratio in crevicular fluid.

2020

Aim Alveolar resorption is one of the most important events in periodontitis. Osteoclast activity is regulated by the ratio between receptor activator of NF-κB ligand (RANKL) and osteoprotegerin (OPG). The aim of this study was to evaluate changes in the RANKL/OPG ratio in crevicular fluid after periodontal treatment. Material and methods A total of 15 patients with periodontitis were included in the study group. Samples were collected from an area with active periodontitis and a healthy area. The RANKL and OPG levels were measured before and after periodontal scaling and root planing (SRP) treatment. The study group was compared to the control group, which included 10 patients without peri…

MaleTeethAlveolar Bone LossOsteoclastsPathology and Laboratory MedicineAntiplatelet TherapyVascular Medicine0302 clinical medicineScaling and root planingOral DiseasesAnimal CellsMedicine and Health SciencesProspective StudiesProspective cohort studyConnective Tissue CellsMultidisciplinarybiologyPharmaceuticsQRGingival Crevicular FluidMiddle AgedHealthy VolunteersTreatment Outcomemedicine.anatomical_structureConnective TissueRANKL030220 oncology & carcinogenesisMedicineFemaleAnatomyCellular TypesPeriodontal IndexResearch Articlemusculoskeletal diseasesmedicine.medical_specialtyScienceOral MedicineHemorrhage03 medical and health sciencesSigns and SymptomsDrug TherapyOsteoprotegerinDiagnostic MedicineOsteoclastInternal medicinemedicineHumansPeriodontitisBonePeriodontal DiseasesAgedPeriodontitisbusiness.industryRANK LigandOsteoprotegerinCase-control studyBiology and Life SciencesRANK LigandCell Biology030206 dentistrymedicine.diseaseBiological TissueEndocrinologyJawCase-Control StudiesChronic Periodontitisbiology.proteinDental ScalingbusinessDigestive SystemHeadPLoS ONE
researchProduct

Do randomized clinical trial selection criteria reflect levels of risk as observed in a general population of acute myocardial infarction survivors? …

2016

IF 4.638; International audience; Background: Few clinical trials have focused on populations with a history of distant myocardial infarction (MI). The PEGASUS trial assessed the impact of dual antiplatelet therapy in such patients, selected by enrichment criteria of high cardiovascular risk. Whether the PEGASUS population reflects the risk of a broader post-MI population is questionable. We analyzed whether 4-year mortality of a routine-practice population would differ according to the inclusion and exclusion criteria used in PEGASUS.Methods: FAST-MI is a nationwide French registry recruiting acute MI patients in November 2005; 2490 patients alive and without recurrent MI at one year were …

MaleTicagrelorMyocardial Infarction030204 cardiovascular system & hematologyCoronary artery diseaselaw.inventionCoronary artery disease0302 clinical medicineRandomized controlled trialRisk FactorslawSecondary PreventionRegistriesSurvivors030212 general & internal medicineMyocardial infarctionRandomized Controlled Trials as TopicAged 80 and overeducation.field_of_studyReperfusion therapyEvidence-Based PharmacotherapyMiddle Aged[ SDV.MHEP.CSC ] Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemST-elevation myocardial infarctionPopulation SurveillanceInclusion and exclusion criteriaFemaleFranceAtherothrombotic EventsCardiology and Cardiovascular MedicineAdultmedicine.medical_specialtyPopulationAcute St-ElevationAcute myocardial infarctionVorapaxar03 medical and health sciences[SDV.MHEP.CSC]Life Sciences [q-bio]/Human health and pathology/Cardiology and cardiovascular systemInternal medicinemedicineHumansMortalityeducationSelection (genetic algorithm)AgedAspirinbusiness.industryPatient SelectionAntiplatelet therapymedicine.diseaseComorbidityClinical trialAdherencePhysical therapyTherapybusinessFollow-Up Studies
researchProduct

Perioperative risk of bleeding with antithrombotic agents in macular surgery: a national, prospective, multicentre study

2020

International audience; Purpose To compare the risk of haemorrhagic complications in elective macular surgery between patients with no antithrombotic (AT) treatment (defined as patients with no history of AT therapy or who discontinued AT therapy) and patients who continued AT treatment during the surgery. Methods E-case report forms were prospectively recorded in a database before vitreoretinal surgery and 1 month after. Data on patient characteristics, surgical techniques, haemorrhagic complications and antithrombotic status were collected. Patients with retinal detachment, proliferative diabetic retinopathy and previous retinal haemorrhage were excluded. Results A total of 748 procedures…

Male[SDV]Life Sciences [q-bio]030204 cardiovascular system & hematologynoncardiac surgeryantiplateletsurgery0302 clinical medicineRisk FactorsAntithromboticMedicineProspective Studiesoral anticoagulantsguidelinesantithrombotic agenteducation.field_of_studyAnticoagulantvitreoretinalRetinal HemorrhageGeneral MedicineDiabetic retinopathy3. Good healthPopulation SurveillanceFemalemacular surgeryhaemorrhagehemorrhagemanagementmedicine.medical_specialtymedicine.drug_classPopulationPostoperative Hemorrhagemaintenance03 medical and health sciencesHumans[SDV.MHEP.OS]Life Sciences [q-bio]/Human health and pathology/Sensory OrganseducationAgedbusiness.industryanticoagulantAnticoagulantsPerioperativeOdds ratioRetinal Perforationsmedicine.diseasedual antiplatelet therapyvitreoretinal surgeryConfidence intervalSurgerywarfarinOphthalmology030221 ophthalmology & optometrybusiness[SDV.MHEP]Life Sciences [q-bio]/Human health and pathologyFollow-Up StudiesRetinal haemorrhage
researchProduct

Ischemic stroke risk during long-term follow up in patients with successful catheter ablation for atrial fibrillation in Korea

2018

The interruption of oral anticoagulation therapy (OAC) after CA of atrial fibrillation (AF) is controversial. The purpose of this study was to evaluate the relationship between successful long-term outcomes of catheter resection and SR maintenance and ischemic stroke risk in Korea. We studied 1,548 consecutive patients who were followed up for more than 2 years after CA of AF. We investigated the incidence of ischemic stroke during long-term follow-up. Compared to the AF recurrence group (n = 619), the sinus rhythm (SR) maintenance group (n = 929) had more paroxysmal AF (74.6% versus 44.4%, p<0.001), smaller LA size (39.9±5.7mm versus 42.3±6.0mm, p<0.001), and younger age (54.2±10.9 years v…

Malemedicine.medical_treatmentAnticoagulant Therapylcsh:Medicine030204 cardiovascular system & hematologyAntiplatelet TherapyPathology and Laboratory MedicineVascular MedicineBrain IschemiaGeographical LocationsElectrocardiography0302 clinical medicineRisk FactorsAtrial FibrillationMedicine and Health SciencesMedicineSinus rhythm030212 general & internal medicinelcsh:ScienceMultidisciplinaryPharmaceuticsIncidence (epidemiology)IncidenceAtrial fibrillationMiddle AgedStrokeCatheterCardiovascular TherapyBioassays and Physiological AnalysisNeurologyCardiologyCatheter AblationFemaleArrhythmiaResearch ArticleBiotechnologymedicine.medical_specialtyCathetersAsiaLong term follow upCerebrovascular DiseasesCardiologyCatheter ablationHemorrhageResearch and Analysis Methods03 medical and health sciencesSigns and SymptomsDrug TherapyDiagnostic MedicineInternal medicineRepublic of KoreaHumansIn patientIschemic StrokeKoreabusiness.industrylcsh:RElectrophysiological TechniquesBiology and Life Sciencesmedicine.diseaseIschemic strokePeople and Placeslcsh:QMedical Devices and EquipmentCardiac ElectrophysiologybusinessFollow-Up StudiesPLoS ONE
researchProduct

Platelet function testing in pigs using the Multiplate® Analyzer.

2019

PLOS ONE 14(8), e0222010 (2019). doi:10.1371/journal.pone.0222010

Platelet AggregationSwinePhysiology030204 cardiovascular system & hematologyPlatelet inhibitionPharmacologyAntiplatelet Therapy0302 clinical medicineOral administrationAnimal CellsPig ModelsMedicine and Health SciencesMedicinePlateletOral AdministrationRoutes of AdministrationMammalsMultidisciplinaryPharmaceuticsQREukaryotaHematologyAnimal ModelsClopidogrelBody FluidsBloodExperimental Organism SystemsVertebratesMedicineAnatomyCellular Typesmedicine.drugResearch ArticleBlood PlateletsPlateletsPlatelet Function TestsScience610Research and Analysis Methods03 medical and health sciencesAnimal modelDrug TherapyAnimalsddc:610Platelet activationBlood CoagulationApplication methodsPharmacologyBlood CellsAspirinbusiness.industryOrganismsBiology and Life Sciences030208 emergency & critical care medicineCell BiologyPlatelet ActivationReference valuesAmniotesPurinergic P2Y Receptor AntagonistsAnimal StudiesbusinessPlatelet Aggregation InhibitorsPloS one
researchProduct